98%
921
2 minutes
20
Harnessing dendritic cells (DC) to treat HIV infection is considered a key strategy to improve anti-HIV treatment and promote the discovery of functional or sterilizing cures. Although this strategy represents a promising approach, the results of currently published trials suggest that opportunities to optimize its performance still exist. In addition to the genetic and clinical characteristics of patients, the efficacy of DC-based immunotherapy depends on the quality of the vaccine product, which is composed of precursor-derived DC and an antigen for pulsing. Here, we focus on some factors that can interfere with vaccine production and should thus be considered to improve DC-based immunotherapy for HIV infection.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305438 | PMC |
http://dx.doi.org/10.3389/fimmu.2018.02993 | DOI Listing |
Ann Intern Med
September 2025
Johns Hopkins University School of Medicine, Baltimore, Maryland (M.S., J.J., K.A.G., M.S., A.T.F.).
Background: With antiretroviral therapy, people with HIV can live a normal lifespan and not transmit HIV. The Ryan White HIV/AIDS Program provides care for over half of people with HIV in the United States.
Objective: To estimate how many HIV infections could result from cessation of Ryan White services or interruptions lasting 18 to 42 months.
PLoS Pathog
September 2025
INSERM UMR 1291, CNRS UMR 5051, Université de Toulouse, Toulouse Institute for Infectious and Inflammatory Diseases, Toulouse, France.
Vδ1 γδ T cells are key players in innate and adaptive immunity, particularly at mucosal interfaces such as the gut. An increase in circulating Vδ1 cells has long been observed in people with HIV-1, but remains poorly understood. We performed a comprehensive characterization of Vδ1 T cells in blood and duodenal intra-epithelial lymphocytes, obtained from endoscopic mucosal biopsies of 15 people with HIV-1 on antiretroviral therapy and 15 HIV-seronegative controls, in a substudy of the ANRS EP61 GALT study (NCT02906137).
View Article and Find Full Text PDFPLoS Biol
September 2025
Department of Virology, Immunology & Microbiology, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States of America.
Despite the success of antiretroviral therapy in suppressing plasma viremia in people living with human immunodeficiency virus type-1 (HIV-1), persistent viral RNA expression in tissue reservoirs is observed and can contribute to HIV-1-induced immunopathology and comorbidities. Infection of long-lived innate immune cells, such as tissue-resident macrophages and microglia may contribute to persistent viral RNA production and chronic inflammation. We recently reported that de novo cytoplasmic expression of HIV-1 intron-containing RNA (icRNA) in macrophages and microglia leads to MDA5 and MAVS-dependent innate immune sensing and induction of type I IFN responses, demonstrating that HIV icRNA is a pathogen-associated molecular pattern (PAMP).
View Article and Find Full Text PDFBackground: Overweight and obesity are major concerns among people living with HIV (PLWH), particularly those on integrase inhibitors, as they elevate the risk of cardiovascular diseases. However, longitudinal data on the burden and risk factors for overweight/obesity in sub-Saharan Africa (SSA) remain limited. This study aimed to estimate the incidence and identify factors associated with overweight and obesity among PLWH who switched to a dolutegravir (DTG)-based ART regimen at Livingstone University Teaching Hospital.
View Article and Find Full Text PDFJ Infect Dev Ctries
August 2025
Department of Microbiology and Parasitology, Faculty of Science, University of Buea, Cameroon.
Introduction: Despite increased national and international funding to combat the human immunodeficiency virus (HIV) pandemic, prison health services remain underfunded, resulting in poor HIV management among inmates. This study assessed viral suppression rates among HIV-positive inmates across four central prisons in Cameroon to evaluate the effectiveness of antiretroviral therapy (ART) in these settings.
Methodology: This cross-sectional study included four central prisons-prisons A, B, C, and D-each located in different regions of Cameroon.